Story
BlossomHill Therapeutics Prices Upsized $150 Million IPO at $16 Per Share

BlossomHill Therapeutics, Inc., a biopharmaceutical firm developing small molecule cancer treatments, announced it has priced its upsized initial public offering to raise $150.0 million in gross proceeds. The company will offer 9,375,000 shares of common stock at a public price of $16.00 per share, according to a press release dated August 6, 2026.
Offering Details
The offering was increased in size from its initial plans, a signal that may suggest strong investor demand. Shares are expected to begin trading on the Nasdaq Global Select Market on August 7, 2026, under the ticker symbol BLSM. The offering is anticipated to close on August 10, 2026, subject to customary closing conditions.
Key figures from the IPO pricing include:
- Shares Offered: 9,375,000
- Price Per Share: $16.00
- Gross Proceeds: $150.0 million, before deducting underwriting discounts and commissions.
- Underwriter Option: Underwriters have a 30-day option to purchase up to an additional 1,406,250 shares at the IPO price.
Company Background and Pipeline
AdBased in San Diego, BlossomHill Therapeutics focuses on developing targeted therapies for cancer. The capital raised from the IPO will likely be used to advance its clinical programs.
The company's lead investigational drugs include BH-30643, an EGFR inhibitor for non-small cell lung cancer, and BH-30236, a CLK inhibitor being developed for acute myeloid leukemia and higher-risk myelodysplastic syndrome.
Market Significance
The IPO is being managed by a syndicate of investment banks, with J.P. Morgan, Leerink Partners, and Guggenheim Securities serving as lead book-running managers. LifeSci Capital and H.C. Wainwright & Co. are acting as joint book-running managers. The successful pricing and upsized nature of the offering provide a key data point on investor appetite for clinical-stage biotechnology companies in the current market.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.